SCHEMBL25327045

SCHEMBL25327045

CS(=O)(=O)c1ccc(-c2ccc(C3CN(C(=O)N4CC5(CC(c6ncn[nH]6)C5)C4)C3)cc2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.39
▸ DPP4 P27487 4/20 0.33
▸ FASN P49327 3/20 0.33
▸ DPP7 Q9UHL4 3/20 0.33
▸ PRKAB2 O43741 3/20 0.32
▸ PRKAG1 P54619 3/20 0.32
▸ PRKAA2 P54646 3/20 0.32
▸ PRKAA1 Q13131 3/20 0.32
▸ PRKAG3 Q9UGI9 3/20 0.32
▸ PRKAG2 Q9UGJ0 3/20 0.32
▸ PRKAB1 Q9Y478 3/20 0.32
▸ SLC6A9 P48067 2/20 0.32
▸ KCNH2 Q12809 2/20 0.32
▸ CYP11B1 P15538 1/20 0.32
▸ CYP11B2 P19099 1/20 0.32
▸ SCD O00767 1/20 0.32
▸ PTGS2 P35354 2/20 0.31
▸ ENPP2 Q13822 1/20 0.31
▸ ATXN2 Q99700 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30700000 0.88 MGLL (0.50) MGLLDPP4FASNDPP7PRKAB2
SCHEMBL25323033 0.87 MGLL (0.39) MGLLFASNENPP2ATXN2
SCHEMBL25324932 0.87 MGLL (0.40) MGLLDPP4FASNDPP7PRKAB2
SCHEMBL31549740 0.80 MGLL (0.40) MGLLDPP4DPP7PRKAB2PRKAG1
SCHEMBL30700021 0.78 MGLL (0.43) MGLLFASNPRKAB2PRKAG1PRKAA2
SCHEMBL25259801 0.74 PRKAB2 (0.42) MGLLDPP4DPP7PRKAB2PRKAG1
SCHEMBL30700353 0.74 MGLL (0.50) MGLLFASNPRKAB2PRKAG1PRKAA2
SCHEMBL25326463 0.74 MGLL (0.41) MGLLFASNPRKAB2PRKAG1PRKAA2
SCHEMBL30012727 0.74 P2RX7 (0.37) DPP4DPP7SLC6A9KCNH2
SCHEMBL27143693 0.74 P2RX7 (0.37) DPP4DPP7SLC6A9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 MGLL 3523/4885DPP4 2629/4885FASN 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback